Hippocratic AI Consolidates Life Sciences Leadership with Acquisition of Grove AI and Key Executive Appointments

The move establishes a dedicated Life Sciences Division and senior executive advisory council to accelerate generative AI across the biopharma and medtech value chain.

PALO ALTO, Calif.--(BUSINESS WIRE)--Hippocratic AI, the global leader and pioneer in patient-facing generative AI healthcare agents, today announced a major expansion of its life sciences business. The company has acquired Grove AI, appointed a President of Life Sciences, launched a world-class Life Sciences Executive Advisory Council, and entered into a strategic collaboration with Boston Consulting Group (BCG). Together, these milestones establish Hippocratic AI as the category leader in deploying safe, scalable, and clinically grounded generative AI across the biopharma and medtech value chain, from R&D and clinical trials to commercialization and post-market patient engagement.

“Real impact in the life sciences sector requires deeply specialized models, exhaustive safety testing, and LLM safety architectures built to operate within highly regulated environments,” said Munjal Shah, Co-founder and CEO of Hippocratic AI. “That is why Hippocratic AI has strategically expanded its life sciences leadership - acquiring Grove AI, appointing a dedicated President of Life Sciences, convening a world-class Executive Advisory Council, and partnering with Boston Consulting Group.”

Hippocratic AI’s generative AI agents are powered by its proprietary Polaris safety architecture, delivering high-fidelity clinical reasoning and enterprise-grade auditability at scale. Backed by more than 150 million clinical interactions to date and following its recent $126M Series C financing, with a portion of proceeds earmarked for M&A, the company is continuing to scale production-ready generative AI agents that life sciences organizations can trust across research, clinical, and patient engagement workflows.

Acquisition of Grove AI to Accelerate Clinical Engagement Capabilities

Hippocratic AI has acquired Grove AI, a leader in agentic AI for pharma R&D and clinical trial operations, uniting two teams aligned around a shared vision of healthcare abundance, expanding access, accelerating research, and removing friction across the life sciences ecosystem. Grove AI’s team and technology now form a core pillar of Hippocratic AI’s Life Sciences Division.

Over the past year, Grove AI’s platform supported more than 10 million patient interactions, uncovering opportunities to automate and transform thousands of slow, manual workflows across clinical research and development.

“At Grove AI, we built the leading agentic AI solution for pharma R&D by working directly with clinical teams and patients at scale,” said Tran Le, Co-Founder of Grove AI. “By joining Hippocratic AI, we can build on that foundation and accelerate the delivery of these capabilities to a much broader set of life sciences organizations, combining our innovation with Hippocratic AI’s enterprise scale.”

The acquisition brings two cornerstone offerings to Hippocratic AI’s life sciences portfolio:

1. AI Agent (“Grace”): an always-on, multilingual AI agent that supports end-to-end patient engagement, recruitment, and follow-up across voice, text, and email.
2. Grove AI PRM™ (Participant Relationship Management): a purpose-built platform that orchestrates AI-driven participant interactions with full transparency, human oversight, and regulatory alignment.

“With our combined expertise, Hippocratic AI and Grove AI are uniquely positioned to lead the agentic AI transformation at a critical inflection point for the life sciences industry,” said Sohit Gatiganti, Co-Founder of Grove AI.

Today, the combined team is actively collaborating with five of the world’s leading global pharmaceutical companies to deploy AI agents for patient and provider engagement at enterprise scale.

Launch of Life Sciences Executive Advisory Panel

To guide product development and ensure real-world relevance, Hippocratic AI has convened a Life Sciences Executive Advisory Panel, featuring seasoned leaders from the world’s most respected pharmaceutical and medical device companies:

• Jim Meyers, former Chief Commercial Officer at Gilead Sciences, who led the launch of 24 products, including 11 blockbuster brands.
• Michael Norton, former VP of Global Medical Affairs at AbbVie, with over 20 years in R&D and medical leadership across AbbVie and Abbott.
• David Pierce, former President of MedSurg, Endoscopy, and Urology at Boston Scientific, where he helped grow the company to over $20B in revenue.
• Richard Klausner, former Director of the National Cancer Institute, former Executive Director at the Gates Foundation, and Co-founder of Altos Labs, a leading biotechnology company with more than $3 billion in funding, as well as Lyell Immunopharma, Juno Therapeutics, and Grail.

This executive advisory panel brings deep expertise across therapeutic areas, commercialization, medical affairs, quality, and device innovation, ensuring Hippocratic AI’s offerings are tuned to the evolving needs of life sciences partners.

“I decided to join Hippocratic AI as an advisor due to the team’s commitment to innovation that puts the patient and patient safety first. Their proven track record of supporting millions of patient clinical calls, powered by the Polaris Constellation Architecture, uniquely positions them to continue to drive meaningful change across life sciences. I am excited to apply my extensive industry experience during this pivotal period to help deepen the company’s vertical expertise and navigate this complex landscape,” said Jim Meyers, former Chief Commercial Officer at Gilead Sciences.

Newly Appointed President of Life Sciences

Leading the Life Sciences Division is Dr. Ahad Wahid, M.D., President of Life Sciences at Hippocratic AI. A former NHS surgeon and member of the UK General Medical Council’s Quality Assurance Board, Dr. Wahid brings deep expertise in patient safety and regulatory rigor. He later spent a decade as a Partner at Boston Consulting Group, where he led global AI and healthcare transformation initiatives and advised executive teams and boards at more than 30 of the world’s leading healthcare organizations. At Hippocratic AI, Dr. Wahid applies this combined clinical and strategic perspective to ensure AI adoption enhances care delivery while meeting the highest safety standards.

“Hippocratic AI is building what life sciences has been waiting for: generative AI that can scale globally without compromising safety or regulatory integrity. The acquisition of Grove AI, combined with our expanded leadership team, advisory council, and collaboration with BCG, gives us the foundation to further operationalize agentic AI across research, clinical, and patient engagement workflows. My focus is ensuring these technologies are deployed responsibly, measurably, and at enterprise scale so innovation translates into real outcomes for patients and organizations alike,” said Dr. Ahad Wahid, M.D., President of Life Sciences at Hippocratic AI.

Strategic Collaboration with Boston Consulting Group

As previously announced last week, Hippocratic AI has entered into a strategic collaboration with Boston Consulting Group (BCG) and BCG X to help pharma and medtech clients adopt generative AI solutions aligned with commercial, R&D, and medical affairs goals. Life sciences requires a strategic roadmap and deep understanding of regulatory requirements. BCG and Hippocratic AI will collaborate to bring integrated AI strategies, implementation services, and measurable ROI to the life sciences sector. This collaboration builds on BCG's AI transformation leadership and Hippocratic AI’s pioneering generative AI healthcare agents, which are designed for safety, patient trust, and scale.

“This collaboration is about closing the value gap in the industry by bringing together Hippocratic AI’s sophisticated AI agent platform, BCG’s strategy and governance expertise, and BCG X’s Health Care Commercial AI solution to help clients turn potential into measurable business value,” said Ashkan Afhkami, BCG managing director and senior partner and global leader for the Health Care practice at BCG X.

About Hippocratic AI

Hippocratic AI has developed the safest generative AI Agents for healthcare. The company believes that generative AI has the ability to bring healthcare abundance to every person in the world. The company focuses on building non-diagnostic patient-facing clinical AI agents and does not allow its agents to be used to prescribe or diagnose. Hippocratic AI has received a total of $404 million in funding and is backed by leading investors, including Andreessen Horowitz, General Catalyst, Kleiner Perkins, Avenir, NVIDIA’s NVentures, Premji Invest, SV Angel, Google’s CapitalG, and numerous health systems. Learn more at https://hippocraticai.com/.